Skip to main content
SpringerLink
Log in

Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?

  • Current Opinion
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Pioglitazone, a peroxisome proliferator-activated receptors (PPAR) agonist, has been authorized for the management of type 2 diabetes since 1999 in the US and since 2000 in Europe. Since then, the risk of bladder cancer associated with pioglitazone use has been a serious concern. Following a warning from the Agence Française de Sécurité Sanitaire des Produits de Santé (Afssaps) [the French Agency for the Safety of Health Products], use of pioglitazone was suspended in France and Germany in June 2011. Elsewhere, restrictions on prescriptions were implemented, though for both the European Medicines Agency and the US Food and Drug Administration, the risk-benefit ratio remains favourable. Since the development of pioglitazone, its risk assessment has suffered from several inaccuracies such as its alleged specificity for the male rat, untrustworthy selective agonism for PPARγ and mistaken risk evaluation in the large PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events), where one case with a benign tumour in the placebo group was counted as a cancer case. It took until 2011 for the epidemiological data to be sufficiently numerous and conclusive to initiate application of safety measures. Today, the increased risk of bladder cancer associated with pioglitazone seems to be real, but the absolute risk is relatively low. However, in the context of weak efficacy in an extensive population of patients exposed to pioglitazone, the risk-benefit balance is now difficult to assess, and prescription restrictions do not ensure safety. For future risk management, the authors propose several suggestions, which involve an increasing role of health authorities and academic organizations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106–18.

    Article  PubMed  Google Scholar 

  2. US Food and Drug Administration. Safety alerts for human medical products: Rezulin (troglitazone) (2000). http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm173081.htm. Accessed 14 Jun 2013.

  3. European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim (2010). http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/09/WC500096996.pdf. Accessed 14 Jun 2013.

  4. US Food and Drug Administration. Approved drug products: Actos (pioglitazone hydrochloride) (1999). http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed 14 Jun 2013.

  5. European Medicines Agency. European public assessment reports: product information for Actos (2013). http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000285/WC500021386.pdf. Accessed 14 Jun 2013.

  6. European Medicines Agency. Assessment report for Actos, Glustin, Competact, Glubrava, Tandemact (2011). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000285/WC500126656.pdf. Accessed 14 Jun 2013.

  7. International Agency for Research on Cancer, World Health Organization. GLOBOCAN (2008). http://globocan.iarc.fr/. Accessed 14 Jun 2013.

  8. Afssaps. Use of medications containing pioglitazone (Actos®, Competact®) suspended (2011). http://www.ansm.sante.fr/var/ansm_site/storage/original/application/4e293bcd0814c025b94d46d7502a0958.pdf. Accessed 14 Jun 2013.

  9. Takeda Pharma. Dear doctor letter (Rote-Hand-Brief) on medicinal products containing pioglitazone (Actos®, Competact®, Tandemact®): increased incidence of bladder cancer [in German] (2011). http://www.bfarm.de/SharedDocs/1_Downloads/EN/vigilance/roteHandBriefe/2011/rhb-pioglitazon.pdf?__blob=publicationFile. Accessed 14 Jun 2013.

  10. US Food and Drug Administration. Actos label information (1999). http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21073lbl.pdf. Accessed 14 Jun 2013.

  11. El Hage J, Orloff D. Rodent carcinogenicity findings associated with PPAR agonists and their regulatory recommendations [abstract]. 3rd International Symposium on PPARS Efficacy and Safety; Monte Carlo; 2005. http://www.lorenzinifoundation.org/ppars2005/abstract_book.pdf. Accessed 30 Jun 2013.

  12. Aoki T. Current status of carcinogenicity assessment of peroxisome proliferator-activated receptor agonists by the US FDA and a mode-of-action approach to the carcinogenic potential. J Toxicol Pathol. 2007;20(4):197–202.

    Article  CAS  Google Scholar 

  13. Cohen SM. Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci. 2005;87(2):322–7.

    Article  PubMed  CAS  Google Scholar 

  14. Dominick MA, White MR, Sanderson TP, et al. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol. 2006;34(7):903–20.

    Article  PubMed  CAS  Google Scholar 

  15. Suzuki S, Arnold LL, Pennington KL, et al. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci. 2010;113(2):349–57.

    Article  PubMed  CAS  Google Scholar 

  16. Tseng CH, Tseng FH. Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2012;30(4):368–402.

    Article  PubMed  CAS  Google Scholar 

  17. Long GG, Reynolds VL, Lopez-Martinez A, et al. Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event. Toxicol Pathol. 2008;36(2):218–31.

    Article  PubMed  CAS  Google Scholar 

  18. Sato K, Awasaki Y, Kandori H, et al. Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats. Toxicol Appl Pharmacol. 2011;251(3):234–44.

    Article  PubMed  CAS  Google Scholar 

  19. Chaffer CL, Thomas DM, Thompson EW, et al. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer. 2006;6:53.

    Article  PubMed  Google Scholar 

  20. Nakashiro KI, Hayashi Y, Kita A, et al. Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol. 2001;159(2):591–7.

    Article  PubMed  CAS  Google Scholar 

  21. Guan YF, Zhang YH, Breyer RM, et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia. 1999;1(4):330–9.

    Article  PubMed  CAS  Google Scholar 

  22. Yoshimura R, Matsuyama M, Segawa Y, et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003;104(5):597–602.

    Article  PubMed  CAS  Google Scholar 

  23. Kawakami S, Arai G, Hayashi T, et al. PPARgamma ligands suppress proliferation of human urothelial basal cells in vitro. J Cell Physiol. 2002;191(3):310–9.

    Article  PubMed  CAS  Google Scholar 

  24. Boiteux G, Lascombe I, Roche E, et al. A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int J Cancer. 2009;124(8):1820–8.

    Article  PubMed  CAS  Google Scholar 

  25. Kassouf W, Chintharlapalli S, Abdelrahim M, et al. Inhibition of bladder tumor growth by 1,1-bis(3′-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res. 2006;66(1):412–8.

    Article  PubMed  CAS  Google Scholar 

  26. Chopra B, Georgopoulos NT, Nicholl A, et al. Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels. Cell Prolif. 2009;42(5):688–700.

    Article  PubMed  CAS  Google Scholar 

  27. Wei S, Yang J, Lee SL, et al. PPARgamma-independent antitumor effects of thiazolidinediones. Cancer Lett. 2009;276(2):119–24.

    Article  PubMed  CAS  Google Scholar 

  28. Alzoubi K, Khabour O, Hussain N, et al. Evaluation of vitamin B12 effects on DNA damage induced by pioglitazone. Mutat Res. 2012;748(1–2):48–51.

    PubMed  CAS  Google Scholar 

  29. Larsson SC, Orsini N, Brismar K, et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia. 2006;49(12):2819–23.

    Article  PubMed  CAS  Google Scholar 

  30. MacKenzie T, Zens MS, Ferrara A, et al. Diabetes and risk of bladder cancer: evidence from a case–control study in New England. Cancer. 2011;117(7):1552–6.

    Article  PubMed  Google Scholar 

  31. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–85.

    Article  PubMed  Google Scholar 

  32. Lubet RA, Fischer SM, Steele VE, et al. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. Int J Cancer. 2008;123(10):2254–9.

    Article  PubMed  CAS  Google Scholar 

  33. La Maestra S, Micale RT, De Flora S, et al. DNA damage in exfoliated cells and histopathological alterations in the urinary tract of mice exposed to cigarette smoke and treated with chemopreventive agents. Carcinogenesis. 2013;34(1):183–9.

    Google Scholar 

  34. Li H, Sorenson AL, Poczobutt J, et al. Activation of PPARgamma in myeloid cells promotes lung cancer progression and metastasis. PLoS One. 2011;6(12):e28133.

    Article  PubMed  CAS  Google Scholar 

  35. European Medicines Agency. Actos: product information as approved by the CHMP on 20 October 2011, pending endorsement by the European Commission (2011). http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/07/WC500109185.pdf. Accessed 14 Jun 2013.

  36. Jaakkola T, Backman JT, Neuvonen M, et al. Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol. 2006;61(1):70–8.

    Article  PubMed  CAS  Google Scholar 

  37. Conlon D. Goodbye glitazars? Br J Diabetes Vasc Dis. 2006;6(3):135–7.

    Article  CAS  Google Scholar 

  38. Hillaire-Buys D, Faillie JL, Montastruc JL, et al. Stay vigilant: a glitazone (pioglitazone) can hide a glitazar! Eur J Clin Pharmacol. 2012;68(12):1681–3.

    Google Scholar 

  39. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89.

    Article  PubMed  CAS  Google Scholar 

  40. Charbonnel B, Dormandy J, Erdmann E, et al. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care. 2004;27(7):1647–53.

    Article  PubMed  Google Scholar 

  41. PROactive Study Executive Committee and Data and Safety Monitoring Committee. PROactive study. Lancet. 2006;367(9515):982.

    Google Scholar 

  42. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180–8.

    Article  PubMed  CAS  Google Scholar 

  43. Mannucci E, Monami M, Lamanna C, et al. Pioglitazone and cardiovascular risk: a comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2008;10(12):1221–38.

    PubMed  CAS  Google Scholar 

  44. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009;32(3):187–202.

    Article  PubMed  CAS  Google Scholar 

  45. Hillaire-Buys D, Faillie JL, Montastruc JL. Pioglitazone and bladder cancer. Lancet. 2011;378(9802):1543–4; author reply 1544–5.

  46. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561–73.

    Article  PubMed  CAS  Google Scholar 

  47. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296(21):2572–81.

    Article  PubMed  CAS  Google Scholar 

  48. Piccinni C, Motola D, Marchesini G, et al. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011;34(6):1369–71.

    Article  PubMed  Google Scholar 

  49. Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case–control study. BMJ. 2012;344:e3645.

    Article  PubMed  Google Scholar 

  50. Li W, Macdonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol. 2013;75(1):254–9.

    Google Scholar 

  51. Mamtani R, Haynes K, Bilker WB, et al. Long-term therapy with thiazolidinediones and the risk of bladder cancer: a cohort study [abstract]. J Clin Oncol. 2012;30 Suppl:Abstract 1503.

  52. Zhu Z, Shen Z, Lu Y, et al. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2012;98(1):159–63.

    Google Scholar 

  53. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34(4):916–22.

    Article  PubMed  CAS  Google Scholar 

  54. Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55(7):1953–62.

    Google Scholar 

  55. Chang CH, Lin JW, Wu LC, et al. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology. 2012;55(5):1462–72.

    Article  PubMed  CAS  Google Scholar 

  56. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012;35(2):278–80.

    Article  PubMed  CAS  Google Scholar 

  57. Colmers IN, Bowker SL, Majumdar SR, et al. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ. 2012;184(12):E675–83.

    Google Scholar 

  58. Kermode-Scott B. Meta-analysis confirms raised risk of bladder cancer from pioglitazone. BMJ. 2012;345:e4541.

    Article  PubMed  Google Scholar 

  59. Bosetti C, Rosato V, Buniato D, et al. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist. 2013;18(2):148–56.

    Google Scholar 

  60. Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med. 2013 [Epub ahead of print].

  61. US Food and Drug Administration. Actos label information (2004). http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21073se8-020_actos_lbl.pdf. Accessed 14 Jun 2013.

  62. US Food and Drug Administration. Actos medication guide (2009). http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021073s037lbl.pdf. Accessed 14 Jun 2013.

  63. US Food and Drug Administration. Drug safety communication: ongoing safety review of Actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure (2010). http://www.fda.gov/%20Drugs/DrugSafety/ucm226214.htm. Accessed 14 Jun 2013.

  64. European Medicines Agency. European Medicines Agency recommends new contra-indications and warnings for pioglitazone to reduce small increased risk of bladder cancer (2011). http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/07/news_detail_001311.jsp&mid=WC0b01ac058004d5c1. Accessed 14 Jun 2013.

  65. European Medicines Agency. European Medicines Agency clarifies opinion on pioglitazone and the risk of bladder cancer: positive benefit-risk balance confirmed as second and third line treatment (2011). http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/10/WC500116936.pdf. Accessed 14 Jun 2013.

  66. US Food and Drug Administration. Actos label information (2011). http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021073s043s044lbl.pdf. Accessed 14 Jun 2013.

  67. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.

    Article  PubMed  Google Scholar 

  68. IMS Health. Top US pharmaceutical products by spending (2012). http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press%20Room/Top-Line%20Market%20Data%20&%20Trends/2011%20Top-line%20Market%20Data/Top_Products_by_Sales.pdf. Accessed 9 Jul 2012.

  69. Montori VM, Fernandez-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann Intern Med. 2009;150(11):803–8.

    Article  PubMed  Google Scholar 

  70. Oliveria SA, Koro CE, Yood MU, Sowell M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndr Clin Res Rev. 2008;2:47–57.

    Article  Google Scholar 

  71. Lewis JD, Ferrara A, Peng T, et al. Cohort study of pioglitazone and bladder cancer in patients with diabetes: fourth interim analysis (8-year) report with data from January 1, 1997 to December 31, 2010 (2012). http://www.encepp.eu/encepp/openAttachment.htm;jsessionid=ac10290dd114e55b0b300e44bfeba88c399468fa486.rlmOahaInljyqA4IpR9BcxaNb3i?field=documents.otherDocument%5B0%5D&id=2903. Accessed 14 Jun 2013.

Download references

Acknowledgments

No sources of funding were used in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. Département de Pharmacologie Médicale et Toxicologie, Centre Régional de PharmacoVigilance, CHRU Montpellier, 371 avenue du Doyen Gaston Giraud, 34295, Montpellier, France

    Jean-Luc Faillie & Pierre Petit

  2. Equipe de PharmacoEpidémiologie INSERM U1027, Faculté de Médecine, Université Paul-Sabatier, Toulouse, France

    Jean-Luc Faillie

  3. Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d’Informations sur le Médicament, Equipe de PharmacoEpidémiologie INSERM U1027, Faculté de Médecine et CHU, Université Paul-Sabatier, Toulouse, France

    Jean-Louis Montastruc

  4. Département de Pharmacologie Médicale et Toxicologie, Centre Régional de PharmacoVigilance, INSERM U1058, Faculté de Médecine et CHRU, Montpellier, France

    Dominique Hillaire-Buys

Authors
  1. Jean-Luc Faillie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pierre Petit
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-Louis Montastruc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dominique Hillaire-Buys
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Luc Faillie.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Faillie, JL., Petit, P., Montastruc, JL. et al. Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?. Drug Saf 36, 693–707 (2013). https://doi.org/10.1007/s40264-013-0086-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-013-0086-y

Keywords

Search

Navigation